Hisamitsu Pharmaceutical : Conclusion of a contract with SSP Co., Ltd. for the partial transfer of assets, related to S-Cup and Lacalut
July 13, 2023 at 02:10 am EDT
Share
This material is an English translation of the press release announced on Jul. 13, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.
Jul. 13, 2023
Conclusion of a contract with SSP Co., Ltd.
for the partial transfer of assets, related to S-Cup and Lacalut
Hisamitsu Pharmaceutical Co., Ltd. (Head Office: Tosu City, Saga Prefecture; President and CEO: Kazuhide Nakatomi; hereinafter "Hisamitsu Pharmaceutical") is pleased to announce that an agreement has been reached, and a contract concluded, with SSP Co., Ltd. (Head Office: Shinjuku- ku, Tokyo; President and CEO: Nikhilesh Kalra; hereinafter "SSP") pertaining to the partial transfer of assets, etc. related to SSP's two brands, S-Cup and Lacalut. Transfer of assets will be executed only after various conditions for closing have been met, such as anti-trust approval and consent from third- party.
With "Promoting the TE-A-TE culture worldwide" as the corporate mission, Hisamitsu has been engaged in business activities to spread the culture of TE-A-TE filled with compassion and caring to people around the world. To meet the needs of an even greater number of customers by making use of our management resources accumulated through our past business activities, we have been searching for activities that would become the new pillar of growth in our 7th medium-term management policy announced on September 17, 2021. Going forward, we are convinced that, by transferring assets relating to S-Cup and Lacalut, two brands of SSP with which we have concluded agreement on this occasion, we can meet the needs of an even greater number of customers.
In the future, Hisamitsu is committed to offering a variety of products and services not limited to patches, and unveiling a wide range of business operations, thereby contributing to improving the quality of life (QOL) of people around the world.
■Assets targeted for transfer
・Target scope: Partial assets related to S-Cup and Lacalut (Product inventory, intellectual property rights, contractual status, etc.)
Tokyo Opera City Tower, 3-20-2Nishi-Shinjuku,Shinjuku-ku, Tokyo
Representative
Nikhilesh Kalra
Established
1927
Line of business
Manufacture and sales of pharmaceuticals, quasi-drugs, foodstuffs, etc.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 13 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 July 2023 06:09:10 UTC.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
HISAMITSU PHARMACEUTICAL CO., INC. 
